Skip to main content
. 2020 Apr 6;132:17–23. doi: 10.1016/j.ejca.2020.03.024

Table 2.

Survey section 1: general (i.e. non-COVID-19) preventive measures for reducing the risk of infections in oncologic patients.

All, n (%) n = 122 Red Zoneb, n (%) n = 39 (32) North, n (%) n = 26 (21) Centre, n (%) n = 18 (15) South and islands, n (%) n = 25 (20)
Vaccination of oncologic pts in view of a systemic therapy No 8 (7) 2 (5) 2 (8) 2 (11) 0
Yes 114 (93) 37 (95) 24 (92) 16 (89) 25 (100)
Which kind of oncologic treatment will the vaccinated pts receivea CT 28 (25) 8 (20) 7 (27) 4 (22) 6 (24)
ICI 12 (11) 4 (10) 4 (15) 1 (5) 1 (4)
HT, TT 16 (14) 6 (15) 4 (15) 2 (11) 3 (12)
None, follow-up 8 (7) 3 (8) 1 (4) 0 2 (8)
All pts 64 (57) 22 (56) 16 (61) 5 (28) 16 (64)
Pts with risk factorsc 42 (37) 14 (36) 7 (27) 8 (44) 7 (28)
Which kind of vaccination is/are adviseda Seasonal flu 72 (64) 27 (69) 17 (65) 11 (61) 12 (48)
Pneumococcal 8 (7) 3 (8) 2 (8) 0 0
Both 42 (37) 11 (28) 8 (31) 4 (22) 13 (52)
Other (tetanus, VZV) 1 (<1) 1 (<1) 0 0 0
Report of seasonal flu cases (e.g. national registry) No 94 (80) 28 (72) 21 (81) 16 (89) 23 (92)
Yes 15 (13) 8 (20) 3 (11) 1 (5) 2 (8)
UNK 9 (7) 3 (8) 2 (8) 1 (5) 0

BMI, body mass index; CT, chemotherapy; HT, hormonal therapy; ICI, immune-checkpoint inhibitors; pts, patients; TT, targeted therapy; UNK, unknown; VZV, varicella zoster virus; COVID-19, novel coronavirus disease.

a

Questions with more than one possible answer.

b

Red Zone at the time of the survey includes the following Italian countries: Lombardia, Emilia Romagna, Veneto.

c

Age ≥75 years, cardiovascular and/or respiratory disease, chronic infections, diabetes, obesity (BMI ≥ 30), immune-suppressive therapies.